4 + 7 How much is the killing power of the procurement with volume? Look at the quotation of the company in the pre-selection stage and know that the company that has reported the low price to be selected will continue to negotiate with the Medicare Bureau this afternoon to determine the final bid price.
Enterprise Quotation and Decline in Pre-winning Stage
In the first two years, when several original research and exclusive varieties were violently rubbed by the country on the floor, the generic pharmaceutical companies standing on the side of watching the excitement definitely did not expect that they would turn to themselves so quickly, and the strength of the Medicare Bureau seemed to be even greater.
Look at the quotations of Chia Tai Tian Qing, AstraZeneca, and Xin Litai. It can only be said that the survival desire of the winning bidder is too strong, and never underestimate the heart of a competitor to win the market.
The results of this afternoon's bargaining will be announced on a certain day, and the outcome will certainly not be better.According to legend:
Finance Union, December 6, the reporter was informed that the national procurement bid negotiation day is still in progress, pre-winning azithromycin enterprises, in the afternoon negotiations with the government, because the government further reduced prices and did not accept, resulting in azithromycin flow standards.In addition, as of now, half of the more than 30 drugs that have all been tenders have not yet determined the final price.
Many people's beliefs seem to be destroyed today …Anyway, that's the way it is, so there's an amateur topic to discuss.4 + 7 After the pre-bid price for procurement with quantity is announced, which type of person is most affected:
1) Secondary market "leek"
Opening in the afternoon, stocks related to collective mining lead the collapse, stocks unrelated to collective mining follow the collapse...It is difficult to say whether confidence can be restored. Anyway, it is said that the growth logic of generic pharmaceutical companies has changed, saying that it is necessary to stay away from pharmaceutical stocks...
After the company wins the bid at a low price, the hospital guarantees the purchase volume, and generic drugs do not need to be marketed to the doctor. The sales expenses are lowered and the department may not need to be opened.
3) Medical representative
Enterprise price cuts, cut profits can only find compensation from sales costs.Generic drugs do not need to be marketed into the hospital, and medical representatives may have to face layoffs (see: Winter is coming?The country's centralized procurement shocks the billion-dollar pharmaceutical market, tens of thousands of pharmaceutical representatives or unemployment...)
On December 3rd, the Top Employers Institute's annual certification dinner was held. Many big pharmaceutical companies have just been on the list, and if they are followed by large-scale cuts, they will be embarrassed.
The two-vote system itself is compressing the living space of some agents. Now that the successful bidder has guaranteed the quantity, he can go directly to the hospital and the manufacturer supplies it directly to the hospital. The living space of the big contractor is not so large.
5) The progress of the pharmacy CRO
conformity assessment itself is very slow (Exclusive · 289 Variety Conformity Assessment Birth and Death Bureau), and companies that are eligible to participate in 4 + 7 procurement through conformity assessment will inevitably shake the confidence of other companies that are doing conformity assessment today.The number of projects CRO can undertake will be reduced.Clinical CRO also has the business of innovative drugs, and the prospects of pharmaceutical CRO are bleak.
From the perspective of industrial integration, if the number of generic pharmaceutical companies shrinks dramatically to 300, generic pharmaceutical projects will not be as much as before, and pharmaceutical CROs will continue to reshuffle and divide, closing the door.
6) People who intend to switch to drug selling